Price T Rowe Associates Inc. MD Acquires 4,327,934 Shares of QIAGEN N.V. $QGEN

Key Points

• Price T Rowe Associates Inc. significantly increased its stake in QIAGEN, acquiring an additional 4,327,934 shares, raising its total ownership to approximately 4.47 million shares, worth $179.5 million.
• Several institutional investors, including Wellington Management Group and Deutsche Bank AG, have also boosted their positions in QIAGEN, highlighting strong interest from hedge funds and institutions.
• QIAGEN reported earnings per share of $0.60 for the latest quarter, aligning with analyst estimates, and announced a dividend of $0.25 with a yield of 52.0% paid to shareholders.

Price T Rowe Associates Inc. MD boosted its holdings in QIAGEN N.V. (NYSE:QGEN - Free Report) by 3,030.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,470,728 shares of the company's stock after buying an additional 4,327,934 shares during the quarter. Price T Rowe Associates Inc. MD owned 2.01% of QIAGEN worth $179,501,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Wellington Management Group LLP raised its position in QIAGEN by 12.2% in the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock worth $972,191,000 after buying an additional 2,656,136 shares during the last quarter. Neuberger Berman Group LLC raised its position in QIAGEN by 102.4% in the 1st quarter. Neuberger Berman Group LLC now owns 19,352 shares of the company's stock worth $767,000 after buying an additional 9,791 shares during the last quarter. Prudential PLC raised its position in QIAGEN by 132.5% in the 1st quarter. Prudential PLC now owns 47,166 shares of the company's stock worth $1,862,000 after buying an additional 26,880 shares during the last quarter. Public Sector Pension Investment Board raised its position in QIAGEN by 5.2% in the 1st quarter. Public Sector Pension Investment Board now owns 113,046 shares of the company's stock worth $4,478,000 after buying an additional 5,593 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of QIAGEN during the 1st quarter valued at about $44,078,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

QIAGEN Stock Performance

Shares of NYSE:QGEN traded down $0.86 during mid-day trading on Wednesday, reaching $48.00. 796,404 shares of the company traded hands, compared to its average volume of 1,312,646. The company's 50 day moving average price is $48.72 and its 200-day moving average price is $44.02. The firm has a market cap of $10.67 billion, a PE ratio of 28.36, a PEG ratio of 2.56 and a beta of 0.64. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. QIAGEN N.V. has a 52 week low of $37.63 and a 52 week high of $51.88.

QIAGEN (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The company had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the company posted $0.55 EPS. The firm's revenue was up 7.7% on a year-over-year basis. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts expect that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on QGEN. UBS Group upped their price target on shares of QIAGEN from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Cowen reaffirmed a "hold" rating on shares of QIAGEN in a research report on Thursday, August 7th. Bank of America upped their price target on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Wall Street Zen lowered shares of QIAGEN from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Finally, Barclays began coverage on shares of QIAGEN in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.